Ozempic maker’s CEO, Lars Jørgensen, steps down after stock dropped 50% in a year

Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, is stepping down amidst increasing pressure in the competitive obesity drug market. The company’s shares have tumbled over 50% since mid-2024 due to market challenges and clinical setbacks. The leadership change comes as the company reports weaker-than-expected sales for its obesity drug Wegovy and cuts its sales forecast.